HD-6277, a Novel GPR40 Agonist, Improves Glucose Homeostasis and Enhanced Glucose-Dependent Insulin Secretion in Beta Cells and Type 2 Diabetic Rats
Abstract
GPR40 is known as free fatty acid receptor 1. Currently, HD-6277, a novel GPR40 agonist, is being developed by Hyundai Pharm in first in human study. The aim of this study was to determine the effects of the novel GPR40 agonist. HD-6277 is a highly potent, selective and orally available small molecule agonist. The potency was measured in vitro and in vivo studies. In vitro potency was determined by HD-6277, TAK-875 and GW95(EC 50 , In vivo glucose lowering effect was determined by oral glucose tolerance test (OGTT) and HbA1c in Sprague-Dawley (SD) rats and various type 2 diabetes rats, respectively. Oral administration of HD-6277 (0.1∼10 mg/kg) once daily reduced plasma glucose excursion and enhanced insulin secretion in GK, DIO, OLETF and ZDF rats. Antidiabetic efficacy compared with Metformin, Glimepiride, Linagliptin, Empagliflozin, Rosiglitazone and Fasiglifam respectively. HD-6277 treatment showed potent anti-hyperglycemic effects than commercially available antidiabetic drugs. GSIS was assessed in INS-1 cells and rats with sulfonylurea and glinides. HD-6277 enhanced insulin excursion in high glucose condition, whereas in low glucose circumstance was not, thus hypoglycemic risk was low. Repeat dosing for 7day in SD rats, glibenclamide (10 mg/kg) and nateglinide (50 mg/kg) caused hypoglycemia but HD-6277 (100 mg/kg) was not. In conclusion, HD-6277 shows a promising new drug candidates to treat type 2 diabetes mellitus. Disclosure D. Kim: Employee; Self; Hyundai Pharm.…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.